Outsourcing-Pharma
1,738 FOLLOWERS
In-PharmaTechnologist.com is a daily news service that provides news stories and data of value to decision-makers in the Pharmaceutical Technology industry.
Outsourcing-Pharma
1M ago
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeuticsâ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform ..read more
Outsourcing-Pharma
1M ago
As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the evolving landscape ..read more
Outsourcing-Pharma
1M ago
From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved out an exciting and unconventional career in science ..read more
Outsourcing-Pharma
1M ago
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application ..read more
Outsourcing-Pharma
1M ago
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization of innovative cellular therapies ..read more
Outsourcing-Pharma
1M ago
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity ..read more
Outsourcing-Pharma
1M ago
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia ..read more
Outsourcing-Pharma
1M ago
Evaxionâs proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer vaccine targets ..read more
Outsourcing-Pharma
1M ago
The US Biosecure Act was passed by the House of Representatives in September and seems likely to become law ..read more
Outsourcing-Pharma
1M ago
Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity with undisclosed investments in its small molecule offerings ..read more